NAPM on user fees
Executive Summary
The National Association of Pharmaceutical Manufacturers submitted comments to the Administrative Conference April 13 objecting to FDA's proposal for user fees. The association objected to FDA's proposal to have one set fee for NDAs and, although a fee was not proposed for ANDAs, questioned the equity of previous fee proposals for ANDAs. NAPM suggested that user fee programs should be centralized, "perhaps in OMB, where necessary expertise, if not already present, can be developed and applied to all agencies".
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.